The acquisition will combine complementary MRD assay portfolios, accelerate commercial adoption, and enhance data-driven insights for biopharma clients. The $1.5B all-stock deal is timed as Personalis' financials improve, with integration and expanded reimbursement expected to drive growth and profitability by 2027.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.